Maren Thurow Takes Charge as New Head of Global Communications at Grünenthal

Maren Thurow Takes Charge at Grünenthal

On May 20, 2025, Maren Thurow officially began her new role as Vice President and Head of Global Communications at Grünenthal. This marks a significant shift within the company as she succeeds Florian Dieckmann, who has played a crucial role in the development of the Communications department since 2021. Maren’s responsibilities include overseeing Grünenthal's communications strategies across various markets, and she will lead a team based at the company's headquarters in Aachen, Germany while directly reporting to CEO Gabriel Baertschi.

Grünenthal is experiencing transformative changes following an impressive financial performance in 2024. The company’s profitability has surged, with adjusted EBITDA having more than tripled since 2017. This growth is attributed to strategic acquisitions and partnerships, such as the purchase of the US-based Valinor Pharma and the integration of Movantik™ in July 2024. Alongside this financial success, Grünenthal has been advancing its critical research and development programs, including progress on the Glucocorticoid Receptor Modulator (GRM) and Nociceptin (NOP) Receptor Agonist programs, as well as ongoing development of its Nav compounds.

Maren’s career prior to joining Grünenthal in 2021 included her role as Head of Global Commercial Communication, followed by her position as Planning Director within the commercial organization. Before her tenure at Grünenthal, she served as a Director at FleishmanHillard, a prominent global PR firm, where she honed her skills in communication strategy and leadership.

Grünenthal stands as a global leader in pain management and related diseases, renowned for its commitment to innovation and improving the lives of patients worldwide. The company operates with a philosophy centered on changing lives for the better and focuses its efforts on achieving its vision of a World Free of Pain. Headquartered in Aachen, Grünenthal has a substantial global presence, boasting affiliates in 28 countries across Europe, Latin America, and the United States. Its products are accessible in approximately 100 countries worldwide. In 2024 alone, Grünenthal employed around 4,300 individuals and registered revenues of €1.8 billion.

As Maren Thurow embraces her new role, the future looks promising for Grünenthal. With her extensive expertise and proven leadership ability, she is set to not only continue the company’s successful trajectory but possibly enhance its outreach and impact in the pharmaceutical industry.

About Grünenthal

Grünenthal is dedicated to addressing pain management and related health issues by providing innovative treatments. The company prioritizes research and the development of cutting-edge technologies aimed at enhancing the quality of life for patients globally. With a robust commitment to its mission, Grünenthal stands resolute in its goal of eradicating pain and fostering a healthier future for all.

For more information, visit Grünenthal's official website and follow the company on their LinkedIn and Instagram pages.